TCT-222 Reperfusion Success, Infarct Size and Clinical Outcomes in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Anterior Myocardial Infarction  by Sanidas, Elias et al.
TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM www.jacctctabstracts2013.com
P
O
S
T
E
R
STCT-221
Prognostic Impact of Concurrence of Diabetes and Renal Insufﬁciency for Acute
Coronary Syndrome
Yun-Kyeong Cho1, In-Sung Chung1, In-Cheol Kim1, Hyoung-Seob Park1,
Hyuck-Jun Yoon1, Hyungseop Kim1, Chang-Wook Nam1, Seung-Ho Hur1,
Yoon-Nyun Kim1, Kwon-Bae Kim1
1Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
Background: Diabetes (DM) and renal insufﬁciency (RI) have been reported as risk
factors for cardiovascular events. However, few studies have evaluated the effect of
DM and RI in acute coronary syndrome (ACS). The aim of this study was to assess the
synergistic effect of DM and RI on cardiovascular outcomes after successful percu-
taneous coronary intervention (PCI) with drug-eluting stent (DES).
Methods: A total of 2158 consecutive patients with ACS who underwent PCI with
DES were divided into 4 groups based on the presence or absence of DM and RI
(glomerular ﬁltration rate <60ml/min/1.73m2). We analyzed the incidence of major
adverse cardiac events (MACE), including cardiovascular death, nonfatal myocardial
infarction and target lesion revascularization after 2-year clinical follow-up.
Results: Primary endpoints occurred in 218 (10.1%) patients. There were signiﬁcant
differences in MACE among 4 groups (282 patients with DM+RI+, 17.7%, 422
patients with DM-RI+, 12.1%; 296 patients with DM+RI-, 8.4%; 1158 patients with
DM-RI-, 7.9%; p<0.001). In Cox analysis, after adjustment for confounding factors,
presence of both DM and RI was independent predictor of MACE.Hazard ratio (95% conﬁdence interval)
No adjustment P value Adjustment P value
DM-RI- 1 1
DM+RI- 1.068 (0.687-1.662) 0.769 1.042 (0.658-1.652) 0.860
DM-RI+ 1.558 (1.106-2.193) 0.011 1.207 (0.806-1.808) 0.362
DM+RI+ 2.353 (1.668-3.321) <0.001 1.932 (1.291-2.892) 0.001Conclusions: Concurrence of DM and RI is an independent predictor of adverse
cardiovascular outcomes in ACS patients undergoing PCI with DES.
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Background: Acute myocardial infarction (MI) is a major cause of death among
patients with diabetes mellitus (DM), even after primary percutaneous coronaryB72 JACC Vol 62/18/Suppl B j October 2intervention (PCI). We sought to evaluate the clinical, angiographic and cardiac MRI
results in patients with and without DM undergoing primary PCI for ST-elevation
myocardial infarction (STEMI).
Methods: In the INFUSE-AMI trial, patients with anterior STEMI due to an occluded
left anterior descending artery (LAD) undergoing primary PCI with bivalirudin anti-
coagulation were randomized to intralesional delivery of intracoronary abciximab vs.
control and to thrombus aspiration or not. Angiographic baseline and post procedure
analysis, cardiac MRI at 30 days and clinical follow-up at 30 days and at 1 year were
performed and compared between DM (n¼51) and non-DM (n¼400) patients.
Results: Patients with DM had more comorbidities and more extensive LAD disease
than non-DM. Primary PCI was equally effective in DM and non-DM in restoring
TIMI-3 ﬂow, ST-segment resolution at 60 minutes and 30-day infarct size (14.3%
[7.1, 24.5] vs. 17.3% [8.1, 23.6], p¼0.55). Stent thrombosis (ST) within 30 days after
primary PCI was higher in DM than non-DM patients (4.3% vs. 0.8%, p¼0.03), and at
1 year DM patients had more major cardiovascular and cerebrovascular events
(MACCE) (16.5% vs. 8.0%, p¼0.04; Figure).Conclusions: Patients with DM presenting with STEMI have a higher baseline risk
proﬁle than those without DM. Although reperfusion success and infarct size were
similar, DM patients experienced more death, reinfarction, stent thrombosis and
revascularization than non-diabetics.
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Background: Percutaneous coronary intervention (PCI) is the recommended reper-
fusion strategy for patients presenting with ST-elevation myocardial infarction
(STEMI). Per the guidelines stent type (bare metal (BMS) vs drug-eluting (DES))
choice is mainly left at the operator’s discretion. Our hypothesis is that stent choice is
inﬂuenced by factors such as insurance, ethnicity, race, and gender.
Methods: Prospectively collected data from 1/1/11 till 12/31/12 at 2 tertiary care
centers in the New York area was obtained. Univariate, bivariate and multivariate
analyses for gender, ethnicity, race, and insurance type were performed. The
primary endpoint was death (index admission or 30-day). The secondary one was
adverse outcome (death, dissection, perforation, MI, CVA, bleeding, transfusion, or
CABG).
Results: Among the 1,442 patients presenting with STEMI who underwent PCI
(1,101 DES, 342 BMS) BMS patients were older, more often of white race and female
gender, with higher prevalence of previous surgery (valve or bypass), bigger vessel
diameter, and smaller stent length than DES patients. DES use was associated with
lower mortality (1% vs 7%, p<0.001) and adverse events (7% vs 23%, p<0.001).
These results were conﬁrmed in multivariate and stratiﬁed analyses.7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
